August 4, 2020 -- Twist Bioscience and Seismic Bio have formed a partnership to discover and optimize antibodies to high-value immuno-oncology targets.
Under the terms of the deal, Twist Bioscience division Twist Biopharma will use its Hyperimmune Libraries -- two human antibody libraries focused on the heavy chain complementary-determining region 3 (CDR3) loop diversity involved in antigen recognition -- to identify antibodies that bind to the specified immuno-oncology targets. Seismic Bio will then use these monoclonal antibodies as building blocks to create bispecific antibody therapeutics, according to the companies.
In addition, Seismic Bio will pay fees to Twist for technology activity and milestones for all compounds discovered through the partnership.
Copyright © 2020 scienceboard.net